durvalumab
astrazeneca
['nsclc', 'lcsm,(-blcsm)', 'durva', 'sclc']
an analysis by &amp; colleagues of treatment options for patients with stage iii unresectable egfr mutant #nsclc showed consolidation egfr tki therapy yielded significantly longer disease free survival than durvalumab #asco23 #lcsm 
Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.